case_images: PMC8378231_01
case_images: MRI showing cerebral metastasis before (A), after three month (B) and after one year (C) of double check point inhibition with ipilimumab and nivolumab.
case_images: fonc-11-684733-g001.jpg
case_images: PMC8378231_01_fonc-11-684733-g001.jpg
case_images: f1
case_images: In the following restaging performed by a PET-CT scan and an MRI of the brain 3 months after starting the therapy, the patient showed a clear response to the therapy with a profound remission of all tumor lesions (Figures 1B, 2B, 3B). In the actual PET-CT scan and MRI of the brain, the patient still showed a profound remission of all tumor lesions, and there was no detectable sign of a relapse (Figures 1C, 2C).
case_images: FDG-PET-CT showing systemic metastasis before (A), after three months (B), and after one year (C) of double check point inhibition with ipilimumab and nivolumab.
case_images: fonc-11-684733-g002.jpg
case_images: PMC8378231_01_fonc-11-684733-g002.jpg
case_images: f2
case_images: In the following restaging performed by a PET-CT scan and an MRI of the brain 3 months after starting the therapy, the patient showed a clear response to the therapy with a profound remission of all tumor lesions (Figures 1B, 2B, 3B). In the actual PET-CT scan and MRI of the brain, the patient still showed a profound remission of all tumor lesions, and there was no detectable sign of a relapse (Figures 1C, 2C).
case_images: Tumor lesions before (A) and after 3 months (B) of double checkpoint inhibition with ipilimumab and nivolumab.
case_images: fonc-11-684733-g003.jpg
case_images: PMC8378231_01_fonc-11-684733-g003.jpg
case_images: f3
case_images: In the following restaging performed by a PET-CT scan and an MRI of the brain 3 months after starting the therapy, the patient showed a clear response to the therapy with a profound remission of all tumor lesions (Figures 1B, 2B, 3B).
case_images: (A) immunotherapy related pneumonitis after four cycles of ipilimumab and nivolumab. (B) regression of pneumonitis after discontinuation of immunotherapy and immunosuppressive treatment with tapered prednisolone.
case_images: fonc-11-684733-g004.jpg
case_images: PMC8378231_01_fonc-11-684733-g004.jpg
case_images: f4
case_images: In March 2020, the patient developed an immunotherapy-related pneumonitis with clinically mild symptoms but clear correlations in CT scans of the lung (Figure 4A) and noticeably reduced diffusion capacity in a subsequent lung-function examination. Because of decreasing signs of pneumonitis in control CT scans (Figure 4B) and an improving diffusion capacity in lung function, prednisolone could be quickly tapered to 7.5 mg, and re-exposure to nivolumab was feasible in June 2020.
case_images: Timeline of the patients' history.
case_images: fonc-11-684733-g005.jpg
case_images: PMC8378231_01_fonc-11-684733-g005.jpg
case_images: f5